Loading market dashboard
hVIVO plc
OPORFHealthcareOTCGB
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
hVIVO PLC's (AIM:HVO) consultancy contract with Decoy Therapeutics, announced on Monday, is a small deal by any financial measure, but Peel Hunt's reading of it points to something more strategically significant for the AIM-listed contract research organisation. The agreement covers a wide range of services to support Decoy's development of its Designable Multi-Antiviral candidates, a novel antiviral category targeting shared mechanisms across multiple respiratory viruses with a single, adaptable therapeutic approach.
hVIVO PLC (AIM:HVO), the clinical development company specialising in human challenge trials, has signed a consultancy contract with Decoy Therapeutics to support the development of a novel class of broad-spectrum respiratory antivirals. The engagement covers translational modelling, regulatory strategy, chemistry, manufacturing and controls consulting, non-clinical development support, and preparation of clinical and regulatory documentation for submissions to European and UK regulators, including the European Medicines Agency and the UK's Medicines and Healthcare products Regulatory Agency.
hVIVO PLC (AIM:HVO), the human challenge trial specialist, will hold a capital markets day on 11 June in Canary Wharf as it seeks to reposition itself as a full-service early clinical development partner. The event will feature speakers from Boehringer Ingelheim, RA Capital, ILiAD Biotechnologies and Decoy Therapeutics, alongside hVIVO's own leadership team.
hVIVO PLC (AIM:HVO) chief executive, Yamin ‘Mo' Khan, talked with Proactive about the company's latest contract win with a new European biotech client for an influenza human challenge trial. Khan explained that the trial is set to begin almost immediately, with most of the revenue expected to be recognised in 2026 and additional contributions extending into 2027.
Shares in hVIVO PLC (AIM:HVO), the human challenge trial specialist, were up 7% to 7.99p, extending a recovery that has seen the stock gain around 25% since the start of the year, after the latest in a run of contract announcements. The catalyst for today's move is the signing of a £6 million clinical trial agreement to conduct an influenza human challenge trial for an unnamed biopharmaceutical company, the latest in a sequence of deals that analysts at Cavendish say is providing a "step change" to revenue visibility for 2026.
The signing of a pivotal phase III human challenge trial for a whooping cough vaccine marks a turning point not just for hVIVO PLC (AIM:HVO), but for the entire human challenge trial model as a credible route to regulatory approval. Until now, human challenge trials have largely been used in earlier-stage drug development, where exposing healthy volunteers to a pathogen under controlled conditions allows researchers to generate proof-of-concept efficacy data quickly and cheaply.
hVIVO PLC (AIM:HVO) chief executive, Yamin “Mo” Khan, talked with Proactive about the company's full-year results, highlighting financial performance, strategic progress and outlook for 2026. Khan explained that despite a challenging macroeconomic environment, the company delivered results in line with expectations, reporting revenue of just under £47 million and a positive EBITDA of over £1 million.
hVIVO plc (OPORF) Q4 2025 Earnings Call Transcript
hVIVO PLC (AIM:HVO), the human challenge trial specialist, reported a sharp fall in revenue and profitability for 2025, but Cavendish argued on Wednesday that the numbers mask a more encouraging underlying story and that the company is better positioned heading into 2026 than the headline figures suggest. The broker, which maintains a 'buy' rating and 16.5p target price against a current share price of 8.7p, kept its 2026 revenue forecast virtually unchanged at £50.3 million following the results, reflecting management guidance for high single-digit growth weighted towards the second half of the year.
hVIVO PLC (AIM:HVO), the AIM-listed human challenge trial specialist, expects high single-digit revenue growth in 2026, weighted to the second half, as it moves past a year of deliberate restructuring. The London-based clinical development company posted revenue of £46.8 million for the year ended 31 December, down from £62.7 million the prior year.
Cavendish has maintained its 'buy' recommendation and 16.5p target price on hVIVO PLC (AIM:HVO) following the clinical development specialist's announcement of a new influenza human challenge trial contract with Traws Pharma. The broker described the deal as consistent with the company's strong offering in the antiviral market.
hVIVO PLC (AIM:HVO) shares rose 11% to 8.18p after the clinical development specialist announced a new influenza human challenge trial contract and unveiled a unified brand identity on the same day, marking what the company says is the completion of its transformation into a fully integrated drug development partner. The trial agreement with Traws Pharma will see hVIVO test tivoxavir marboxil, an investigational single-dose oral antiviral targeting seasonal influenza and bird flu, at its Canary Wharf quarantine facilities.
The AIM-listed clinical development specialist completes its transformation with a new deal and a rebrand consolidating four service lines under one identity. hVIVO PLC (AIM:HVO) has signed a contract to run an influenza human challenge trial for Traws Pharma on the same day it unveiled a new brand identity, marking the completion of its transformation into a fully integrated drug development partner.
